X T L Biopharmaceuticals Ltd
Change company Symbol lookup
Select an option...
XTLB X T L Biopharmaceuticals Ltd
RBLX Roblox Corp
JMIA Jumia Technologies AG
MYDX MyDx Inc
WHF WhiteHorse Finance Inc
INDB Independent Bank Corp (Massachusetts)
SNOW Snowflake Inc.
FAUDX Strategic Advisers® Short Duration Fund
FFBC First Financial Bancorp
SMEBF Sime Darby Bhd
Go

Health Care : Biotechnology | Small Cap Value
Based in Israel
Company profile

XTL Biopharmaceuticals Ltd., incorporated on March 9, 1993, is a biopharmaceutical company. The Company is engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company’s developed drug candidate is hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). Its hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. Its rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM).

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$4.45
Day's Change
0.30 (7.23%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.69
Day's Low
4.00
Volume
(Heavy Day)
Volume:
3,989,602

10-day average volume:
377,732
3,989,602

LAWSUITS FILED AGAINST FGEN, EBS and PTON - Jakubowitz Law Pursues Shareholders Claims

5:41 am ET June 10, 2021 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / June 10, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

FibroGen, Inc. (NASDAQ:FGEN)

CONTACT JAKUBOWITZ ABOUT FGEN:

https://claimyourloss.com/securities/fibrogen-inc-loss-submission-form/?id=16761&from=1

Class Period: October 18, 2017 - April 6, 2021

Lead Plaintiff Deadline: June 11, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Emergent Biosolutions Inc. (NYSE: EBS)

CONTACT JAKUBOWITZ ABOUT EBS:

https://claimyourloss.com/securities/emergent-biosolutions-inc-loss-submission-form/?id=16761&from=1

Class Period: April 24, 2020 - April 16, 2021

Lead Plaintiff Deadline: June 18, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Emergent's Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent's facility led to a string of FDA citations; (iii) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants' public statements about Emergent's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis.

Peloton Interactive, Inc. (NASDAQ:PTON)

CONTACT JAKUBOWITZ ABOUT PTON:

https://claimyourloss.com/securities/peloton-interactive-inc-loss-submission-form/?id=16761&from=1

Class Period : September 11, 2020 - May 5, 2021

Lead Plaintiff Deadline : June 28, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) in addition to the tragic death of a child, Peloton's Tread+ had caused a serious safety threat to children and pets as there were multiple incidents of injury to both; (2) safety was not a priority to Peloton as defendants were aware of serious injuries and death resulting from the Tread+, yet did not recall or suggest a halt of the use of the Tread+; (3) as a result of the safety concerns, the U.S. Consumer Product Safety Commission ("CPSC") declared that the Tread+ posed a serious risk to public health and safety and urgently recommended that consumers with small children cease using the Tread+; (4) the CPSC also found a safety threat to Tread+ users if they lost their balance; and (5) as a result of the foregoing, defendants' statements about Peloton's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Image: https://www.accesswire.com/users/newswire/images/651232/Jakubowitz_CTA-1.png

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

JAKUBOWITZ LAW

1140 Avenue of the Americas

9th Floor

New York, New York 10036

T: (212) 867-4490

F: (212) 537-5887

SOURCE: Jakubowitz Law

View source version on accesswire.com:

https://www.accesswire.com/651232/LAWSUITS-FILED-AGAINST-FGEN-EBS-and-PTON--Jakubowitz-Law-Pursues-Shareholders-Claims

comtex tracking

COMTEX_388083320/2457/2021-06-10T05:41:16

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.